千金药业(600479) - 2018 Q1 - 季度财报

Financial Performance - Operating revenue rose by 4.98% to CNY 690,326,657.69 year-on-year[6] - Net profit attributable to shareholders increased by 22.37% to CNY 33,941,603.37 compared to the same period last year[6] - Basic earnings per share increased by 22.39% to CNY 0.0973[6] - The profit attributable to shareholders of the parent company was CNY 33,941,603.37, up 22.4% from CNY 27,737,539.41 in the previous year[35] - Basic and diluted earnings per share for Q1 2018 were CNY 0.0973, compared to CNY 0.0795 in Q1 2017, reflecting a growth of 22.5%[35] - Net profit for Q1 2018 reached CNY 42,422,124.99, representing a 23% increase compared to CNY 34,497,671.49 in Q1 2017[34] Cash Flow - Cash flow from operating activities decreased by 57.18% to CNY 20,607,771.58 compared to the previous year[6] - The net cash flow from operating activities decreased by 57.18% year-on-year, amounting to CNY 20,607,771.58, due to increased tax payments[20] - The company reported a cash flow from operating activities of CNY 19,110,516.20 for Q1 2018, compared to CNY 15,407,615.32 in Q1 2017, indicating a growth of 24%[37] - Net cash flow from operating activities decreased to ¥20,607,771.58 from ¥48,127,310.81, reflecting a decline of 57.1%[39] - Total cash outflow from operating activities was ¥1,046,030,103.62, up from ¥850,008,656.02, reflecting a rise of 23.1%[39] Assets and Liabilities - Total assets increased by 1.87% to CNY 3,348,250,885.89 compared to the end of the previous year[6] - Total current assets increased to CNY 2,487,548,833.50 from CNY 2,429,237,726.97, representing a growth of approximately 2.4%[25] - Total non-current assets amounted to CNY 860,702,052.39, slightly up from CNY 857,643,461.93, indicating a marginal increase of 0.1%[26] - Total liabilities rose to CNY 1,064,660,989.43 from CNY 1,045,713,417.43, an increase of approximately 1.4%[27] - Total equity increased to CNY 2,283,589,896.46 from CNY 2,241,167,771.47, representing a growth of about 1.9%[27] - The company’s total liabilities to equity ratio stands at approximately 46.6%[27] Shareholder Information - The total number of shareholders reached 26,673 at the end of the reporting period[9] - The largest shareholder, Zhuzhou State-owned Assets Investment Holding Group, holds 28.53% of the shares[9] Investment and Income - Investment income increased by 127.80% year-on-year, reaching CNY 410,560.59, driven by higher returns from matured financial products[19] - Other income doubled compared to the previous year, amounting to CNY 2,915,573.45, due to increased government subsidies[19] - The company reported a significant increase in fair value gains of 4527.59% year-on-year, reaching CNY 3,150,492.94[19] - Non-recurring gains and losses totaled CNY 5,558,526.46 after tax adjustments[10] Accounts Receivable and Inventory - Accounts receivable grew by 85.29% year-on-year, totaling CNY 287,788,211.53, attributed to expanded sales and collection policies[14] - Other receivables increased by 79.65% compared to the previous year, amounting to CNY 137,079,685.47, mainly due to increased petty cash[14] - Inventory increased to CNY 413,550,730.60 from CNY 376,324,551.24, reflecting a growth of about 9.9%[25] Future Outlook - The company plans to continue expanding its market presence and investing in new product development to drive future growth[34] - The company anticipates potential significant changes in cumulative net profit compared to the previous year, but no specific details were provided[23]